drugset / Trial / NCT00072839
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
Timeline
- Start
- 2003-11-12
- Primary completion
- 2005-07-28
- Completion
- 2005-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teduglutide | Peptide | 0.05 mg/kg | Subcutaneous |
| Subject | Teduglutide | Peptide | 0.1 mg/kg | Subcutaneous |
| Subject | Teduglutide | Peptide | 0.2 mg/kg | Subcutaneous |